HC Wainwright Reiterates Buy Rating on argenx SE
HC Wainwright maintains its buy rating on argenx SE, setting a $940 price target, a 5.95% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on argenx SE, targeting a price of $940.
- HC Wainwright's $940 price target implies 5.95% upside from argenx SE's ($ARGX) current $887.18 share price.
- Shares of argenx SE traded at $852.5 on Thursday, with a market cap of approximately $56.5 billion.
- FMR LLC and Artisan Partners adjusted their positions in argenx SE, with FMR LLC reducing by 601,285 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating on argenx SE (NasdaqGS: ARGX), maintaining a target price of $940. Analyst Douglas Tsao confirmed the rating on June 25, 2026. The stock was trading around $852.5 on Thursday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in argenx SE
Several institutional investors have adjusted their holdings in argenx SE. FMR LLC reduced its stake by 601,285 shares, leaving it with 4,991,034 shares valued at approximately $3.64 billion, a 10.8% decrease. PRICE T ROWE ASSOCIATES INC /MD/ slightly increased its position by 12,631 shares, now holding 3,374,955 shares worth about $2.46 billion, a 0.4% increase. JANUS HENDERSON GROUP PLC expanded its stake by 83,568 shares, resulting in a total of 2,541,732 shares valued at $1.85 billion, a 3.4% increase. CAPITAL WORLD INVESTORS added 339,982 shares, growing its position by 17.7% to 2,256,216 shares, valued at $1.65 billion. Meanwhile, ARTISAN PARTNERS LIMITED PARTNERSHIP cut its holding by 288,960 shares, down 16.4% to 1,467,982 shares, valued at $1.07 billion.
argenx SE Stock Down 13.3%
On Thursday, shares of argenx SE (NasdaqGS: ARGX) traded near $852.5. The company has a market capitalization of about $56.5 billion and a P/E ratio of 40.2. Its forward P/E stands at 24.7, and it has a beta of -0.033, indicating low volatility compared to the market. Over the past 52 weeks, the stock has ranged from $510.06 to $934.62. The 50-day moving average is $822.67, and the 200-day moving average is $811.28.
$ARGX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
argenx SE reported revenues of approximately $4.74 billion with a growth rate of 62.6%. The company achieved a net margin of 31.4%. Its earnings per share (EPS) stood at $22.47. The next earnings release is scheduled for July 23, 2026.
Analysts Set New Price Targets
On June 25, 2026, HC Wainwright & Co. reiterated its buy rating with a $940 price target. Morgan Stanley maintained its buy rating on June 24, 2026, with a target of $1,180. Wells Fargo, on June 1, 2026, maintained its buy rating with a $1,291 target. The consensus among analysts is a strong buy, with an average target price of $1,018.14 based on 22 analyst opinions.
About argenx SE
argenx SE is a biotechnology company based in Amsterdam, Netherlands. It specializes in developing therapies for autoimmune diseases. The company offers treatments like VYVGART for generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx is also working on a range of other treatments, including efgartigimod for various autoimmune conditions. The company was founded in 2008 and is led by CEO Ms. Karen Massey.
Bottom Line
HC Wainwright's reiterated buy rating for argenx SE highlights continued optimism for the company's prospects. Investors follow analyst ratings closely for insight into potential stock performance. As a reminder, analyst ratings are based on past data and don't guarantee future results.
Get argenx SE alerts
New 13F filings, insider trades, and analyst moves on $ARGX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.